AI Article Synopsis
- - The development of myeloproliferative neoplasms (MPNs) is linked to specific gene mutations in JAK2, MPL, or CALR, which are critical for diagnosis according to WHO standards.
- - In a study involving 1382 patients, rare and unexpected genetic profiles emerged, leading to challenges in accurately diagnosing MPNs due to mixed mutations and the need for additional genetic testing.
- - The findings highlight the importance of confirming mutations through direct Sanger sequencing and considering germline DNA alongside next-generation sequencing (NGS) for accurate interpretation and treatment decisions.
Article Abstract
Introduction: The pathogenesis of myeloproliferative neoplasms (MPNs) is closely related to the acquisition of specific molecular alterations in JAK2, MPL, or CALR genes, the presence of which represent major diagnostic criteria in the WHO classification. The CALR exon 9 insertions and deletions are very heterogeneous, and their detection mainly relies on polymerase chain reaction (PCR) fragment length analysis.
Methods: We report on the rare nonclassical profiles that we observed among the 1382 patients analyzed by PCR fragment length analysis. In difficult cases, we tested germline DNA and performed NGS analysis.
Results: We faced some troubling results because of the presence of several unexpected peaks. Our investigations showed that they resulted from a mix of isolated or double somatic mutations combined with germline alterations which could be misleading for a correct diagnosis. The precise interpretation of such difficult cases is mandatory as a misinterpretation could lead to the prescription of cytoreductive drugs to nondiseased persons or to an absence of treatment in true MPN patients.
Conclusion: Our observations showed that every mutation should be verified by direct Sanger sequencing, and we show that sometimes it may be necessary to study germline DNA and to complement with NGS analysis to precisely interpret the molecular alterations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.13282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CALR frameshift mutation detection in myeloproliferative neoplasms by microfluidic chip analysis.
Lab Med
December 2024
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, United States.
Background: CALR mutation analysis is routinely used to diagnose BCR/ABL1-negative myeloproliferative neoplasms. The 2 most common CALR mutations are a 52-base pair (bp) deletion and a 5-bp insertion, which account for approximately 85% of cases.
Methods: To evaluate our new microfluidic chip assay, we tested CALR mutant and wild-type specimens that were previously analyzed using conventional methods at a reference laboratory.
HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.
Leukemia
December 2024
Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Although multiple genetic events are thought to play a role in promoting progression of the myeloproliferative neoplasms (MPN), the individual events that are associated with the development of more aggressive disease phenotypes remain poorly defined. Here, we report that novel genomic deletions at chromosome 12q14.3, as detected by a high-resolution array comparative genomic hybridization plus single nucleotide polymorphisms platform, occur in 11% of MPN patients with myelofibrosis (MF) and MPN-accelerated/blast phase (AP/BP) but was not detected in patients with polycythemia vera or essential thrombocythemia.
View Article and Find Full Text PDFMolecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasm in a Moroccan Population.
Asian Pac J Cancer Prev
November 2024
Cytogenetics Laboratory, Pasteur Institute of Morocco (IPM), 1 Place Louis Pasteur, 20360 Casablanca, Morocco.
Introduction: Myeloproliferative neoplasms (MPN) are associated with clonal hematopoiesis, genomic instability, hemostasis dysregulation, and immune response. Classic BCR-ABL1 negative myeloproliferative neoplasms (BCR-ABL1 negative MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are frequently associated with somatic abnormalities in JAK2, CALR, and MPL. Mutant clones induce an inflammatory immune response leading to immuno-thrombosis.
View Article and Find Full Text PDFAnterior Uveitis After Discontinuation of Janus Kinase Inhibitor, Ruxolitinib.
J Med Cases
August 2024
Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama City 700-8558, Japan.
Primary myelofibrosis shows widespread fibrosis in the bone marrow and is part of myeloproliferative neoplasms in which gene mutations in hematopoietic stem cells lead to abnormal clonal expansion of one or more lineage of myeloid and erythroid cells and megakaryocytes. Janus kinase (JAK) inhibitors are the main therapeutic regimen for primary myelofibrosis which harbors gene mutations, resulting in continuous activation of JAK-STAT signaling pathway. Since JAK inhibitors modulate immunological state, the administration would have a potential for uveitis.
View Article and Find Full Text PDFPrevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm-A single-center study from North India.
Indian J Pathol Microbiol
October 2024
Department of Hematology, SGPGI, Lucknow, Uttar Pradesh, India.
Article Synopsis
- * Methods: The study involved screening for these mutations using various techniques like ARMS PCR, allele-specific PCR, Sanger sequencing, and commercial kits among 378 MPN cases diagnosed in a North Indian tertiary care center over a span of 6.5 years.
- * Results: JAK2V617F mutations were prevalent in most PV, ET
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!